Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve™ Antimicrobial Wound Gel
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has signed a three-year distribution agreement with Qatar Datamation Systems (QDS) for its revyve™ Antimicrobial Wound Gel in the Qatar wound care market. This marks Kane's second distribution agreement in the Middle East and fourth overall for revyve™.
The company has previously secured distribution agreements for revyve™ in the United Arab Emirates, United States, Colombia, Costa Rica, and Panama. Kane Biotech also plans to commercialize revyve™ in Canada following its recent ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ha firmato un accordo di distribuzione triennale con Qatar Datamation Systems (QDS) per il suo gel antimicrobico revyve™ nel mercato della cura delle ferite in Qatar. Questo segna il secondo accordo di distribuzione di Kane in Medio Oriente e il quarto complessivo per revyve™.
L'azienda ha precedentemente ottenuto accordi di distribuzione per revyve™ negli Emirati Arabi Uniti, Stati Uniti, Colombia, Costa Rica e Panama. Kane Biotech ha anche in programma di commercializzare revyve™ in Canada a seguito della recente certificazione ISO 13485:2016 per il programma di audit dei dispositivi medicali (MDSAP).
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ha firmado un acuerdo de distribución por tres años con Qatar Datamation Systems (QDS) para su gel antimicrobiano revyve™ en el mercado de cuidado de heridas de Qatar. Esto marca el segundo acuerdo de distribución de Kane en Medio Oriente y el cuarto en total para revyve™.
La compañía ya había asegurado acuerdos de distribución para revyve™ en los Emiratos Árabes Unidos, Estados Unidos, Colombia, Costa Rica y Panamá. Kane Biotech también planea comercializar revyve™ en Canadá tras su reciente certificación ISO 13485:2016 para el Programa de Auditoría Única de Dispositivos Médicos (MDSAP).
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF)는 카타르 데이터메이션 시스템(QDS)과 3년 배급 계약을 체결하여 카타르 상처 치료 시장에서 revyve™ 항균 상처 젤을 제공합니다. 이는 Kane의 중동에서 두 번째 배급 계약이며 revyve™에 대한 네 번째 계약입니다.
회사는 이미 아랍에미리트, 미국, 콜롬비아, 코스타리카 및 파나마에서 revyve™에 대한 배급 계약을 확보했습니다. Kane Biotech는 또한 최근 ISO 13485:2016 의료기기 단일 감사 프로그램(MDSAP) 인증을 받은 후 캐나다에서 revyve™를 상용화할 계획입니다.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) a signé un accord de distribution de trois ans avec Qatar Datamation Systems (QDS) pour son gel antibactérien revyve™ sur le marché des soins des plaies du Qatar. Cela marque le deuxième accord de distribution de Kane au Moyen-Orient et le quatrième au total pour revyve™.
L'entreprise avait déjà obtenu des accords de distribution pour revyve™ aux Émirats Arabes Unis, aux États-Unis, en Colombie, au Costa Rica et au Panama. Kane Biotech prévoit également de commercialiser revyve™ au Canada suite à sa récente certification ISO 13485:2016 pour le programme d'audit unique des dispositifs médicaux (MDSAP).
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) hat einen drei-jährigen Vertriebsvertrag mit Qatar Datamation Systems (QDS) für sein revyve™ Antimikrobielles Wundgel im qatariischen Wundversorgungmarkt unterzeichnet. Dies ist das zweite Vertriebsabkommen von Kane im Nahen Osten und das vierte insgesamt für revyve™.
Das Unternehmen hat zuvor Vertriebsabkommen für revyve™ in den Vereinigten Arabischen Emiraten, den Vereinigten Staaten, Kolumbien, Costa Rica und Panama gesichert. Kane Biotech plant auch, revyve™ in Kanada zu kommerzialisieren, nachdem es kürzlich die ISO 13485:2016-Zertifizierung für das Medizinprodukte-Einzel-Audit-Programm (MDSAP) erhalten hat.
- Signed a three-year distribution agreement for revyve™ Antimicrobial Wound Gel in Qatar
- Expanding global commercialization with the second distribution agreement in the Middle East
- Fourth distribution agreement for revyve™ product
- Recent obtention of ISO 13485:2016 MDSAP certification
- None.
Company’s Second Distribution Agreement in Middle East
WINNIPEG, Manitoba, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution agreement with Qatar Datamation Systems (“QDS”) for its revyve™ Antimicrobial Wound Gel in the Qatar wound care market.
“Kane continues its global commercialization of revyve™ with its second distribution agreement in the Middle East,” said Marc Edwards, President & CEO. “We’re looking forward to partnering with QDS to bring revyve™ to market in Qatar and we are confident that the product will be well-received in the region.”
This is Kane’s fourth distribution agreement for revyve™. Kane has previously announced distribution agreements with Razan Medical & Surgical Equipment Trading LLC in the United Arab Emirates (UAE), ProgenaCare Global LLC in the United States and Salud Pharma S.A. for Colombia, Costa Rica and Panama. Kane also recently announced its intent to commercialize revyve™ in Canada following the obtention of its ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. DispersinB®, Aledex™, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
About QDS
With 23 years of dutiful service to Qatari hospitals and clinics, QDS Healthcare Division is dedicated to developing and maintaining relationships with leading manufacturers so we can provide the latest healthcare innovations to medical practices throughout Qatar. Besides providing top-notch medical technology, we’re also driven to provide high levels of customer satisfaction. What that means for our clients is quality they can trust and people who care.
For more information:
| Marc Edwards | Ray Dupuis |
| Chief Executive Officer | Chief Financial Officer |
| Kane Biotech Inc | Kane Biotech Inc |
| medwards@kanebiotech.com | rdupuis@kanebiotech.com |
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
What is the new distribution agreement Kane Biotech (KNBIF) has signed for revyve™ Antimicrobial Wound Gel?
How many distribution agreements does Kane Biotech (KNBIF) now have for revyve™?
In which countries does Kane Biotech (KNBIF) have distribution agreements for revyve™?
What recent certification has Kane Biotech (KNBIF) obtained for commercializing revyve™ in Canada?
